Our world-class team of 26 scientists, drug developers, clinicians and computational systems biologists in Geneva and Barcelona
is changing the paradigm for drug discovery and development in neurodevelopmental disorders.
Lynn is CEO and founder of STALICLA. Driven by her lifelong involvement with the autism community, Lynn has instituted a paradigm shift in the neurodevelopmental disorder (NDD) drug discovery space by pioneering the creation of the first NDD specific precision medicine discovery platform. Lynn has assembled a world-class cross functional team of drug developers, clinicians and data scientists in STALICLA’s Geneva (Drug Development) and Barcelona (Discovery and Data Science) units as well as a unique collaborative network of academic leading research centers & hospitals in the US. Lynn has authored and co-authored 7 patents and is the recipient of a brain Foundation award for “outstanding leadership towards the advancement of treatments for patients with Neurodevelopmental disorders”.
A biotech entrepreneur, Lynn has a strong business background, starting her career at the World Economic Forum and with a leading Swiss venture capital firm. Before founding STALICLA, she was Head of Partnerships at the University of Geneva and has held senior business development positions at several entities including IFJ AG. EPFL Innovation Park and Tech Tour. Lynn holds master’s degrees in economic history and political sciences from ICP Paris, in corporate communication from NEOMA Business School and in drug discovery and clinical development from the University of Geneva Faculty of Medicine.
The DDS unit leverages on a first in class computational biology machine learning platform to identify specific biological subgroups and bring precision medicine to patients living with Neuro Developmental Disorders. DDS comprises 11 highly skilled members including computational biologists, human geneticists, data scientists, chemo-informaticians and developers.
Emre has 15 years of experience in computational data analysis with an emphasis on translational systems medicine, disease bioinformatics and network pharmacology. He spent several years as a postdoctoral scholar at Harvard Medical School and Northeastern University in the USA, where he pioneered the development of in silico drug efficacy screening using computational modeling of integrative multi-omics data. He was an investigator in EU funded consortia projects for drug toxicity and efficacy modeling during his appointments at the Research Programme in Biomedical Informatics at the Hospital del Mar Research Institute (IMIM) in Spain and at the Pharmacology & Personalised Medicine department at Maastricht University in the Netherlands. He is an alumni of "From Science to Business" program of ESADE Business & Law School in Barcelona. He has a track record of scientific innovation, with more than 40 peer-reviewed publications and has authored/co-authored 4 patents.
Laura brings 15 years of experience in computational biology research with a solid background in autism genetics, as well as a strong personal involvement and commitment with the autism community. After graduating with honors in Biotechnology, she obtained a M.S. degree in Proteomics and a Ph.D. in Bioinformatics at the University of Barcelona. She conducted her Ph.D. research work at the Barcelona Supercomputing Center, which resulted in important contributions to the field of Computational Structural Biology. Before joining STALICLA, Laura spent 5 years as a postdoctoral researcher at the David Geffen School of Medicine at the University of California Los Angeles (UCLA), where she co-led large-scale whole-genome sequencing analyses resulting in the identification of several novel autism risk genes with an unprecedented contribution from inherited risk variation. Since joining STALICLA in 2019, Laura has co-authored 4 patent applications focused on advancing precision medicine for patients with neurodevelopmental disorders.
Bringing drug candidates to clinical stage through late pre-clinical development and regulatory entry preparation. DDU comprises 17 highly skilled members.
Jean-Marc has been part of the management team of STALICLA since 2017. He is a seasoned Operations and Project Manager with 10 years of international experience in academic research and 12 years in the Pharmaceutical and Biotech field. He has played Instrumental roles in directing and improving processes, enhancing productivity, and implementing technology solutions in various drug/medtech development projects. He is skilled in spearheading research and innovation activities in corporate settings and has strong experience in developing and maintaining partnerships with key internal and external stakeholders. Jean-Marc holds a Ph.D. in Cellular Physiology and has authored 44+ articles and several patents.
Baltazar has 25 years of experience in the pharmaceutical industry where he held multiple senior management roles in clinical neuroscience and biomarker development. In 1996, Baltazar started his pharmaceutical development career with Pharmacia – UpJohn as Associate Director CNS-Clinical Development, before transitioning to the position of Senior Director of Clinical Genomics. He then joined Novartis in 2004 as Head of the Neuroscience Biomarker department before taking over the position of Executive Director Neuroscience, Translational Medicine at the Novartis Institutes of Biomedical Research. Baltazar has led numerous CNS, rare disease and Neuropsychiatry clinical trials and benefits from international recognition in the fields of Neurodegeneration and Neurodevelopmental disorders. He has been a leading figure in conducting registration studies for 2 positive NDAs. Baltazar is a neurologist by training and he is adjunct Professor of Neurology and Neurosurgery at MacGill University. Baltazar has co-authored more than 25 patents and more than 80 peer review publications.
Xavier Liogier D’Ardhuy
Ph.D. - Neuropsychologist Advisor in NDDs
Former CTD at STALICLA (2019-2020). Xavier has 20 years of experience in NDD early clinical development including Autism, Down Syndrome and Schizophrenia.
Oliver brings more than 15 years of experience in non-clinical and early clinical drug development. In previous roles as Global Project Director and Non-Clinical Development & Phase 1 Project Director at PregLem and Gedeon Richter, Oliver substantially contributed to the successful registration of fibroid treatment Esmya®. More recently, as ObsEva’s Vice President of Non-Clinical Development and Phase 1, he brought a number of treatment candidates to IND stage in the US, Europe or China and supported several development programs up to marketing authorization application. His interests include all aspects of non-clinical, early clinical and translational drug development. Oliver holds a doctorate in Veterinary Medicine from the University of Munich and post-graduate degrees in biostatistics, toxicology and public health. He is the author or co-author of more than 25 peer-reviewed publications and 8 patents.
Eric has more than 20 years of experience in the pharmaceutical industry, mainly in Neurosciences, covering operational activities and project management from early to late phase of development in Europe, US, Asia and Latin America (FIH, Proof of Concept, Phase 2 up to post-marketing studies and supporting investigational initiated trials).
In previous roles, Eric leaded operational oversight of the blockbuster escitalopram program at Lundbeck. In his career, Eric developed a strong background in CNS, supporting and conducting successfully various clinical trials in various indications like Schizophrenia, Major Depressive Disorder, Generalized Anxiety Disorder, Social Phobia, Alcohol Use Disorder, Sleep Disorder or Treatment Resistance depression.
Eric holds a PhD in Molecular and cellular biology from the University of Pierre and Marie Curie, Paris coupled by a postgraduate education at HEC Paris (Management, Strategy and Leadership).
Results-driven Finance Executive with over 15 years of leadership experience as Auditor then CFO in a wide range of industries (e. g. Real Estate construction, Fine-Art transport and storage, Fitness, Audit and Hotel Industry), with public and private entities of all sizes, François possesses a wide range of skills he has applied with success with many SMEs. Autonomous and independent François has widely recognised human and technical skills, specifically within finance function implementation and improvement, ERP development and personalisation, IT systems and internal processes automation and improvement. François graduated from the Hotel School of Lausanne, HEC-Lausanne and holds the Federal Diploma as a Chartered Accountant.